Home
Diseases
Pancreatic Cancer

Pancreatic Cancer

Disease

Also known as: late-stage pancreatic cancer

Disease Profile

Pancreatic cancer is a highly lethal malignancy, most commonly pancreatic ductal adenocarcinoma, often diagnosed late because early symptoms are nonspecific.

Category: gastrointestinal malignant neoplasm
Prevalence: ACS estimates for 2026 in the U.S. are about 67,440 new pancreatic cancer cases and about 52,980 deaths.

Related News

Multiple Studies Link Accelerated Biological Aging to Rising Early-Onset Cancer in Younger Generations

Jun 29, 2026

Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.

Cantargia Reports 2025 Financials, Secures Financing to Accelerate Nadunolimab Development

Jun 21, 2026

Cantargia reported full year 2025 financial results with net sales of SEK 316.7 million and cash of SEK 281.8 million. The company secured a SEK 124 million financing package to advance clinical development of nadunolimab, including a phase Ib study combining it with a RAS inhibitor in pancreatic cancer.

Clinical Trials Transform Cancer Care: Patient Outcomes and Precision Medicine Advance

Jun 19, 2026

Clinical trials are offering new options for cancer patients, with some achieving long-term survival even with advanced disease. Precision medicine programs are expanding access to these trials by identifying patients with specific tumor mutations, reshaping oncology care.

Pancreatic Cancer mRNA Vaccine Shows Promise as U.S. Funding Cuts Stall Research

Jun 12, 2026

Personalized mRNA vaccines showed promise in pancreatic cancer trials with 7 of 16 patients in remission after five years. Stage 2 melanoma patients saw a 50% decreased death risk with personalized mRNA vaccines. U.S. funding cuts and policy shifts have stalled domestic mRNA cancer research while companies move trials abroad.

AI and mRNA Cancer Vaccine Shows 49% Reduction in Melanoma Relapse at ASCO 2026

Jun 11, 2026

Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.

Experimental Pill Daraxonrasib Nearly Doubles Survival in Advanced Pancreatic Cancer Trial

Jun 01, 2026

An experimental pill called daraxonrasib nearly doubled survival for patients with advanced pancreatic cancer in a clinical trial, marking a significant advance for a deadly disease. The drug targets a mutated protein previously considered "undruggable" and reduced the risk of death by 60% compared to chemotherapy.

FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer

May 21, 2026

The FDA approved Novocure’s Optune Pax, a wearable tumor-treating fields device, for pancreatic cancer in combination with chemotherapy. Phase III PANOVA-3 data showed delayed pain progression and improved one-year overall survival in inoperable locally advanced disease.

New Strategies to Boost Immunotherapy Response in Pancreatic Cancer and Melanoma

May 01, 2026

Researchers identify DPY30 as an epigenetic target to sensitize pancreatic tumors to immunotherapy. UC San Diego researchers redirect CMV immunity against pancreatic cancer in preclinical models. A Fred Hutch researcher receives ACS grant to study immunotherapy resistance in melanoma.

EMA Initiates Rolling Review of OS Therapies' OST-HER2 for Osteosarcoma

Apr 30, 2026

EMA has initiated a rolling review of OS Therapies' OST-HER2 for preventing recurrence in fully resected pulmonary metastatic osteosarcoma. A potential conditional marketing authorization decision is expected in Q4 2026, with a confirmatory Phase 3 trial planned for Q3 2026 in Australia.

mRNA cancer vaccine research shows promise as U.S. funding debate continues

Apr 22, 2026

mRNA cancer vaccines showed promising pancreatic cancer trial results and boosted tumor-fighting drugs in other research. U.S. officials canceled $500 million in vaccine funding, while the NCI is backing a $200 million cancer vaccine partnership.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07612566	Immune Repertoire Decoding for Chronic Pancreatitis-to-Pancreatic Cancer Risk Stratification	NOT_YET_RECRUITING
NCT07612046	A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening	RECRUITING
NCT07606430	Comparison of a Short Modified Metal Stent Versus Plastic Stent as a Bridge to Surgery in Pancreatic Cancer With Malignant Biliary Obstruction	NOT_YET_RECRUITING	NA
NCT07605819	Pancreatic Cancer Screening Using the Enzeavour Assay in Japan	RECRUITING	NA
NCT07605702	The Canopy Cancer Collective Clinical Registry Protocol	NOT_YET_RECRUITING
NCT07597772	Preliminary Trial of SNA014 for Pancreatic Cancer	RECRUITING	EARLY_PHASE1
NCT07595835	CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer	RECRUITING	PHASE1/PHASE2
NCT07592338	Agreement Between Large Language Model-Generated Treatment Recommendations With Guideline-Based and Tumor Board Decisions in Gastrointestinal Cancer	COMPLETED
NCT07591480	Barriers And Facilitators To Clinical Trial Enrollment: A Qualitative Study Of Pancreatic Cancer Patients	NOT_YET_RECRUITING
NCT07589569	An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer	RECRUITING	PHASE2